Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination

Cutaneous and Ocular Toxicology

Volumn 33, Issue 3, 2014, Pages 181-183

  Aydin, Fatma ^a   Yuksel, Esra Pancar ^a   Senturk, Nilgun ^a   Canturk, Tayyar ^a   Turanli, Ahmet Yasar ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Cyclosporine; Malignancy; Methotrexate; Psoriasis

Indexed keywords

CYCLOSPORIN; METHOTREXATE; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICATION THERAPY MANAGEMENT; PSORIASIS; QUESTIONNAIRE; TREATMENT OUTCOME; DRUG COMBINATION; MIDDLE AGED; NEOPLASMS; TURKEY;

ADULT; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PSORIASIS; QUESTIONNAIRES; TURKEY;

EID: 84906669926     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2013.825805     Document Type: Article

References (13)

1. Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999;141:279-282.
2. Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006;31:520-524.
3. Orion E, Matz H, Wolf R. The life-threatening complications of dermatologic therapies. Clin Dermatol 2005;23:182-192.
4. Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989;2:723-731.
5. Kurki PT. Safety aspects of the long term cyclosporin A therapy. Scand J Rheumatol Suppl 1992;95:35-38.
6. Suzuki M, Hirano S, Ito H, et al. Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology 2007;12:774-776.
7. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60:1001-1017.
8. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007;34: 322-331.
9. Bailin PL, Tindall JP, Roenigk Jr HH, Hogan MD. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospectiveprospective analysis. JAMA 1975;232:359-362.
10. Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982;50:869-872.
11. Khopkar U, Bhor U. Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy. Indian J Dermatol Venereol Leprol 2008;74:379-382.
12. Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992;26: 836-840.
13. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211-216.